TICKERNERD
Menu
MBRXMBRXHealthcare · Biotechnology

MBRX Stock Forecast: Moleculin Biotech, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.77
−0.88% on the day

The 3 Wall Street analysts covering Moleculin Biotech, Inc. hold a median 12-month price target of $3 — +288.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.1M
Ticker Nerd rank
25 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$0.0
Operating income−$7.6M
Net income−$7.6M
Free cash flow−$6.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.1%
1M
+26.7%
YTD
−76.6%
1Y
−92.5%
From 52W high
−94.2%
From 52W low
+100.8%
$0
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Moleculin Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Revisions
72
Volatility
67
Accruals
44
Issuance
32
Growth
28
Value
17
Quality
14
Momentum
2

Size (90): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26MBRXHigh $31.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $2.00Median $3.00High $31.00

The green dot is the last close — the median target sits +288.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Aug 2026HC Wainwright & Co.MaintainsBuy$22 → $3.00
24 Mar 2026HC Wainwright & Co.ReiteratesBuy$22
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
11 Dec 2025HC Wainwright & Co.MaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 June 2025HC Wainwright & Co.ReiteratesBuy—
9 June 2025HC Wainwright & Co.AssumesBuy$4.00
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025Maxim GroupUpgradeBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2024Maxim GroupMaintainsBuy—
12 Apr 2024Roth MKMMaintainsBuy—
26 Mar 2024Maxim GroupMaintainsBuy—
14 Dec 2023HC Wainwright & Co.InitiatesBuy—
18 Apr 2023Roth MKMMaintainsBuy—
24 Mar 2023OppenheimerReiteratesOutperform—
18 July 2022OppenheimerAssumesOutperform$14
17 Oct 2019OppenheimerInitiatesOutperform$2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MBRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Moleculin Biotech, Inc. returned −92.5% against +16.3% for the S&P 500, dividends included.

MBRX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Oct 25Jan 26Apr 26Jul 26MBRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Moleculin Biotech, Inc. (MBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1371.6%

Higher than 1% of US stocks

Return on assets
−84.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Moleculin Biotech, Inc. (MBRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Moleculin Biotech, Inc. has a market value of $15.1M and an enterprise value of $8.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$30.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$25.4M.

  • Shares outstanding: 7.1M.

  • Trailing P/E: 0.1×; forward P/E: −0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Moleculin Biotech, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

MBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MBRXMoleculin Biotech, Inc.$15.1M
25
DAREDaré Bioscience, Inc.$15.2M
27
PASGPassage Bio, Inc.$15.3M
43
LSTALisata Therapeutics, Inc.$15.3M
56
HINDVyome Holdings, Inc.$14.7M
72
NIKINiki Biosolutions, Inc.$14.7M
12
CNSYCerenome, Inc.$15.4M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Moleculin Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MBRX news & analysis

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

GlobeNewsWire · 14 Sept 2026positive

Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings. The presentations will examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer.

Why it matters — A MBRX watcher would care because the presentations highlight new scientific data for Annamycin, its key drug candidate, across multiple research forums.

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

GlobeNewsWire · 11 Sept 2026neutral

Moleculin Biotech announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing. The company made the announcement on September 11, 2026.

Why it matters — This provides MBRX watchers with access to the company's latest corporate presentation from a major investment conference.

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Zacks Investment Research · 24 Aug 2026positive

Moleculin Biotech (MBRX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher based on this improved outlook.

Why it matters — A Zacks upgrade signals increased analyst optimism about MBRX's earnings prospects, which is directly relevant to investors tracking the company's outlook.

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

GlobeNewsWire · 14 Aug 2026positive

Moleculin Biotech reported Q2 2026 financial results and highlighted progress in its pivotal MIRACLE trial for Annamycin in relapsed/refractory AML, noting positive interim data showing complete remission rates three times higher than the control arm. The company also reported a cash position expected to fund operations into Q1 2027, including $9.3 million raised after quarter-end.

Why it matters — A MBRX watcher would care because the MIRACLE trial is approaching key milestones, including a 90-patient enrollment target in September 2026 and an unblinded efficacy readout expected between December 2026 and February 2027.

FAQ

Frequently asked questions about MBRX stock

What is the MBRX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Moleculin Biotech, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBRX stock a buy right now?

Of the 3 analysts covering Moleculin Biotech, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Moleculin Biotech, Inc. 25 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBRX?

As at 19 Sept 2026, Moleculin Biotech, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will MBRX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +288.0% from the last close, and Ticker Nerd's factor model ranks Moleculin Biotech, Inc. 25 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBRX stock forecast for 2030?

No analyst covering Moleculin Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $31 over the next 12 months.

How has MBRX stock performed over the past year?

Moleculin Biotech, Inc. returned -92.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Moleculin Biotech, Inc. do?

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections.

What is the latest news on MBRX?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings". Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings. The presentations will examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer.

Company

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and other tumor indications, including soft tissue sarcoma lung metastases. The company also advances programs aimed at difficult viral diseases, reflecting a broader approach to unmet medical needs in oncology and virology. Moleculin Biotech works as a specialty drug developer, with research and clinical operations designed to move product candidates through late-stage development and regulatory review. Based in Houston, Texas, the company occupies a niche position in the biopharmaceutical market, where it contributes experimental treatment options for conditions with limited current therapies.

CEO Mr. Walter V. Klemp · 17 employees · United States · https://moleculin.com